Ocular allergy/inflammation:

Indications for: LOTEMAX

Steroid-responsive ocular diseases. Post-op inflammation after ocular surgery.

Clinical Trials:

Post-Operative Inflammation

  • Placebo-controlled clinical studies demonstrated that Lotemax is effective for the treatment of anterior chamber inflammation as measured by cell and flare. 

Giant Papillary Conjunctivitis

  • Placebo-controlled clinical studies demonstrated that Lotemax was effective in reducing the signs and symptoms of giant papillary conjunctivitis after 1 week of treatment and continuing for up to 6 weeks while on treatment. 

Seasonal Allergic Conjunctivitis

  • A placebo-controlled clinical study demonstrated that Lotemax was effective in reducing the signs and symptoms of allergic conjunctivitis during peak periods of pollen exposure. 

Uveitis

  • Controlled clinical studies of patients with uveitis demonstrated that Lotemax was less effective than prednisolone acetate 1%. Overall, 72% of patients treated with Lotemax experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with 1% prednisolone acetate. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with Lotemax and 6% with prednisolone acetate 1%.

Adult Dosage:

Steroid-responsive diseases: 1–2 drops into affected eye(s) 4 times daily. May give up to 1 drop every 1hr within the 1st week of therapy. Post-op: 1–2 drops into operated eye(s) 4 times daily beginning 24hrs after surgery, continue for 2wks post-op.

Children Dosage:

Not established.

LOTEMAX Contraindications:

Ocular fungal, viral, or mycobacterial infections.

LOTEMAX Warnings/Precautions:

Reevaluate if no improvement after 2 days. Prescribe initially and renew only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Contact lenses (remove during therapy and when eyes are inflamed). Pregnancy. Nursing mothers.

See Also:

LOTEMAX Classification:

Steroid.

Adverse Reactions:

Local reactions (eg, blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation. May delay healing and increase bleb formation after cataract surgery; also, Oint/Gel: anterior chamber inflammation, conjunctival hyperemia, corneal edema, eye pain.

Metabolism:

Hepatic.

Drug Elimination:

Fecal.

How Supplied:

Susp—5mL, 10mL, 15mL, Oint—3.5g; Gel—5g